William Blair begins coverage of Amgen at outperform

Amgen Inc. coverage was initiated by William Blair & Co. analyst John Sonnier with an outperform rating, saying the company has the most exciting late-stage product pipeline in the industry. Shares of the Thousand Oaks, Calif., biotechnology company were down $0.09, or 0.11%, at $79.80 on volume of 7,644,946 shares versus the three-month running average of 8,461,080 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.